Nanobiotix Closes $100M Global Offering, Extends Cash Runway into 2029
NBTX has more than doubled off its 52-week low of $3.64.
Summary
Nanobiotix has successfully closed its $100 million global offering, including the full exercise of the underwriters' option, securing funding to extend its operational runway into 2029.
Key Events · Financing and Capital Events · NBTX
-
Global Offering Closed
Nanobiotix announced the closing of its global offering, raising approximately $100 million in gross proceeds.
-
Underwriters' Option Fully Exercised
The underwriters fully exercised their option to purchase additional shares, contributing to the final proceeds.
-
Extended Cash Runway
The company expects the net proceeds, combined with existing cash, to fund operations into 2029.
-
Offering Details
2,218,467 Ordinary Shares (including ADSs) and 345,099 Pre-Funded Warrants were issued at an offering price of $38.98 per ADS, representing a 14.92% discount to the recent VWAP.
Analysis · NBTX · Life Sciences
This filing confirms the successful closing of Nanobiotix's global offering, raising approximately $100 million in gross proceeds, including the full exercise of the underwriters' option. The capital infusion significantly strengthens the company's balance sheet, extending its cash runway into 2029, which is critical for funding ongoing clinical trials and platform development. While the offering was priced at a discount, its oversubscription and full exercise of the option indicate strong investor demand.
At the time of this filing, NBTX was trading at $40.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $3.64 to $57.14. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.